Yep – timely article..
Table of Contents
- Psychedelic Research Issues
- Big Pharma Giant Eli Lilly Acquiring Psychedelic Maker AtaiBeckley
- Legal Oregon Psilocybin Affordability Issues
- Synthetic Psilocybin Concerns in New Jersey
- Natural Versus Synthetic Psychedelic Drugs
- Balancing Healing, Research, and Safety
Part of the tradeoff is that new synthetic drugs can be much more expensive and often deliver more targeted effects. However, classical psychedelics can be more holistic or intense. But they are not as respected or lucrative.
New research into psychedelic medicine is promising news to those with mental health conditions who can benefit in the coming years.
But the question is who will have access? Will these naturally inexpensive, formerly illegal compounds be sold back to those who need them at prices only feasible for the wealthy?
This is occurring with magic mushrooms or psilocybin, DMT, along with Molly, Ecstasy, or MDMA.
Psychedelic Research Issues
The expenses of psychedelic research partially come from balancing regulations for Schedule I substances with complex research. The process demands strict compliance with the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) in every aspect. That includes participant selection, handling, project design, and ongoing informed consent.
To conduct clinical trials on Schedule I psychedelics, preclinical data must demonstrate that the product is reasonably safe before human trials begin. Companies must file an Investigational New Drug (IND) application with the FDA and a DEA Form 222, and get approved on both. The FDA recently released a legal psychedelic drug guide to help navigate the process.
Read more at
